Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F18%3AN0000010" target="_blank" >RIV/00209775:_____/18:N0000010 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209701/pdf/AMS-14-33992.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209701/pdf/AMS-14-33992.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/aoms.2018.79002" target="_blank" >10.5114/aoms.2018.79002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Popis výsledku v původním jazyce

Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardiographic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ven-tricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mono-nuclear leukocytes/mm2 and/or > 7 T-lymphocytes/mm2) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference – LVEF improvement of 12.0 ± 11.4% vs. 18.3 ± 12.6%, decrease in NYHA class of 0.7 ± 0.7 vs. 1.0 ± 0.7, decline in NT-proBNP of 1335 ± 1933 ng/l vs. 1942 ± 3242 ng/l and decrease in infiltrating leukocytes of 11.1 ± 15.8 vs. 6.7 ± 23.0 cells/mm2 and T-lymphocytes of 5.8 ± 15.1 vs. 1.8 ± 10.9 cells/mm2 (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.

Název v anglickém jazyce

Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Popis výsledku anglicky

Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardiographic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ven-tricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mono-nuclear leukocytes/mm2 and/or > 7 T-lymphocytes/mm2) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference – LVEF improvement of 12.0 ± 11.4% vs. 18.3 ± 12.6%, decrease in NYHA class of 0.7 ± 0.7 vs. 1.0 ± 0.7, decline in NT-proBNP of 1335 ± 1933 ng/l vs. 1942 ± 3242 ng/l and decrease in infiltrating leukocytes of 11.1 ± 15.8 vs. 6.7 ± 23.0 cells/mm2 and T-lymphocytes of 5.8 ± 15.1 vs. 1.8 ± 10.9 cells/mm2 (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Archives of Medical Science - Atherosclerotic Diseases

ISSN

2451-0629

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

9

Strana od-do

1245-1253

Kód UT WoS článku

000448045000005

EID výsledku v databázi Scopus

2-s2.0-85055781554